tissue-agnostic drugs

Patient access pitfalls, regulatory inconsistencies hamper tissue agnostic drugs
BioCentury
Fri, 04/26/19 - 07:41 pm
FDA
ASCO
oncology
drug development
patients
clinical trials
tissue-agnostic drugs